GLP-1群雄逐鹿!诺和诺德失速,礼来紧逼,石药、瀚森能否突围?

医药经济报
31 Jul

国产GIP-1出海能否掘金全球市场?继上个月与阿斯利康达成重磅BD之后,7月30日,石药集团再度出手,与美国生物制药公司Madrigal Pharmaceuticals达成一项总价值超20亿美元的重磅License-out交易。根据协议,石药集团将口服GLP-1受体激动剂的全球权益授权给合作伙伴,交易包含1.2亿美元首付款、最高19.55亿美元的里程碑付款以及基于产品净销售额的双位数分成。今年以来...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10